85 related articles for article (PubMed ID: 9024823)
1. Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y.
Shichinohe T; Senmaru N; Furuuchi K; Ogiso Y; Ishikura H; Yoshiki T; Takahashi T; Kato H; Kuzumaki N
J Surg Res; 1996 Dec; 66(2):125-30. PubMed ID: 9024823
[TBL] [Abstract][Full Text] [Related]
2. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice.
Takeuchi M; Shichinohe T; Senmaru N; Miyamoto M; Fujita H; Takimoto M; Kondo S; Katoh H; Kuzumaki N
Gene Ther; 2000 Mar; 7(6):518-26. PubMed ID: 10757026
[TBL] [Abstract][Full Text] [Related]
3. Suppression of various human tumor cell lines by a dominant negative H-ras mutant.
Ogiso Y; Sakai N; Watari H; Yokoyama T; Kuzumaki N
Gene Ther; 1994 Nov; 1(6):403-7. PubMed ID: 7584106
[TBL] [Abstract][Full Text] [Related]
4. [Inhibition of ras-dependent transformation by using dominant negative ras mutant N116Y].
Yokoyama T
Hokkaido Igaku Zasshi; 1995 May; 70(3):459-71. PubMed ID: 7590597
[TBL] [Abstract][Full Text] [Related]
5. Suppression of Erk activation and in vivo growth in esophageal cancer cells by the dominant negative Ras mutant, N116Y.
Senmaru N; Shichinohe T; Takeuchi M; Miyamoto M; Sazawa A; Ogiso Y; Takahashi T; Okushiba S; Takimoto M; Kato H; Kuzumaki N
Int J Cancer; 1998 Oct; 78(3):366-71. PubMed ID: 9766573
[TBL] [Abstract][Full Text] [Related]
6. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma.
Tsuchida T; Kijima H; Hori S; Oshika Y; Tokunaga T; Kawai K; Yamazaki H; Ueyama Y; Scanlon KJ; Tamaoki N; Nakamura M
Cancer Gene Ther; 2000 Mar; 7(3):373-83. PubMed ID: 10766343
[TBL] [Abstract][Full Text] [Related]
8. Expression profiling of the influence of RAS mutants on the TGFB1-induced phenotype of the pancreatic cancer cell line PANC-1.
Fensterer H; Giehl K; Buchholz M; Ellenrieder V; Buck A; Kestler HA; Adler G; Gierschik P; Gress TM
Genes Chromosomes Cancer; 2004 Mar; 39(3):224-35. PubMed ID: 14732924
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth.
Chen J; Ouyang ZG; Zhang SH; Zhen YS
Oncol Rep; 2007 Jun; 17(6):1445-51. PubMed ID: 17487403
[TBL] [Abstract][Full Text] [Related]
10. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation.
Aoki K; Yoshida T; Matsumoto N; Ide H; Sugimura T; Terada M
Mol Carcinog; 1997 Oct; 20(2):251-8. PubMed ID: 9364215
[TBL] [Abstract][Full Text] [Related]
11. Inhibited neoplastic phenotype by the c-Ha-ras antisense RNA.
Lu GR; Wu CJ; Ke Y; Xiong X; Li YJ; Liu JM; Xu Y; Xu W; Li JY; Deng GR
Sci China B; 1991 Dec; 34(12):1485-91. PubMed ID: 1801843
[TBL] [Abstract][Full Text] [Related]
12. Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells.
Zhu Z; Kleeff J; Kayed H; Wang L; Korc M; Büchler MW; Friess H
Mol Carcinog; 2002 Nov; 35(3):138-47. PubMed ID: 12410565
[TBL] [Abstract][Full Text] [Related]
13. Hammerhead ribozyme specifically inhibits mutant K-ras mRNA of human pancreatic cancer cells.
Tsuchida T; Kijima H; Oshika Y; Tokunaga T; Abe Y; Yamazaki H; Tamaoki N; Ueyama Y; Scanlon KJ; Nakamura M
Biochem Biophys Res Commun; 1998 Dec; 253(2):368-73. PubMed ID: 9878544
[TBL] [Abstract][Full Text] [Related]
14. Peptides designed from molecular modeling studies of the ras-p21 protein induce phenotypic reversion of a pancreatic carcinoma cell line but have no effect on normal pancreatic acinar cell growth.
Kanovsky M; Michl J; Botzolaki G; Morin J; Kovac C; Chung DL; Chie L; Friedman FK; Pincus MR
Cancer Chemother Pharmacol; 2003 Sep; 52(3):202-8. PubMed ID: 12783204
[TBL] [Abstract][Full Text] [Related]
15. Tumor growth suppression by adenovirus-mediated introduction of a cell-growth-suppressing gene tob in a pancreatic cancer model.
Yanagie H; Tanabe T; Sumimoto H; Sugiyama H; Matsuda S; Nonaka Y; Ogiwara N; Sasaki K; Tani K; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 May; 63(4):275-86. PubMed ID: 18657378
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.
Zhang YA; Nemunaitis J; Samuel SK; Chen P; Shen Y; Tong AW
Cancer Res; 2006 Oct; 66(19):9736-43. PubMed ID: 17018633
[TBL] [Abstract][Full Text] [Related]
17. Suppression of colorectal cancer growth using an adenovirus vector expressing an antisense K-ras RNA.
Nakano M; Aoki K; Matsumoto N; Ohnami S; Hatanaka K; Hibi T; Terada M; Yoshida T
Mol Ther; 2001 Apr; 3(4):491-9. PubMed ID: 11319909
[TBL] [Abstract][Full Text] [Related]
18. Molecular target-based therapy of pancreatic cancer.
Lebedeva IV; Sarkar D; Su ZZ; Gopalkrishnan RV; Athar M; Randolph A; Valerie K; Dent P; Fisher PB
Cancer Res; 2006 Feb; 66(4):2403-13. PubMed ID: 16489047
[TBL] [Abstract][Full Text] [Related]
19. Medroxyprogesterone acetate inhibits human pancreatic carcinoma cell growth by inducing apoptosis in association with Bcl-2 phosphorylation.
Abe M; Yamashita J; Ogawa M
Cancer; 2000 May; 88(9):2000-9. PubMed ID: 10813710
[TBL] [Abstract][Full Text] [Related]
20. The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer.
Jin K; Park S; Ewton DZ; Friedman E
Cancer Res; 2007 Aug; 67(15):7247-55. PubMed ID: 17671193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
